Up until the pandemic, Pfizer produced in the region of 200 million vaccines per annum. Once the company’s mRNA vaccine was approved by regulators, attention turned to getting the vaccine to as many people around the world as possible. The urgency to thwart the effects of the pandemic trumped many of the deliberations that occur in calmer times. Today, manufacturers have to cope with the lingering effects of the pandemic, along with geopolitical tensions and economic pressures. Many of the measures taken by Pfizer were only applicable at a time of acute stress, while others have applications going forward. It’s critical for manufacturers and suppliers to understand the difference.